{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,9]],"date-time":"2026-11-09T16:32:14Z","timestamp":1794241934903,"version":"4.9.0"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2013,4,1]],"date-time":"2013-04-01T00:00:00Z","timestamp":1364774400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Adv Therapy"],"published-print":{"date-parts":[[2013,4]]},"DOI":"10.1007\/s12325-013-0023-6","type":"journal-article","created":{"date-parts":[[2013,4,18]],"date-time":"2013-04-18T05:18:01Z","timestamp":1366262281000},"page":"337-353","source":"Crossref","is-referenced-by-count":8,"title":["Efficacy and Safety of Dipeptidyl Peptidase-4 Inhibitors in Combination with Metformin"],"prefix":"10.1007","volume":"30","author":[{"given":"Andrea D.","family":"Fass","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer A.","family":"Gershman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2013,4,15]]},"reference":[{"key":"23_CR1","unstructured":"Januvia [package insert]. Northumberland, United Kingdom: Merck & Co., Inc."},{"key":"23_CR2","unstructured":"Onglyza [package insert]. Princeton, New Jersey: Bristol-Myers Squibb; December 2011."},{"key":"23_CR3","unstructured":"Tradjenta [package insert]. Ridgefield, Connecticut: Boehringer Ingelheim Pharmaceuticals, Inc; September 2012."},{"key":"23_CR4","unstructured":"Nesina [package insert]. Deerfield, Illinois: Takeda Pharmaceuticals America, Inc; January 2013."},{"key":"23_CR5","unstructured":"Galvus [prescribing information]. Nurenberg, Germany: Novartis Pharmaceuticals."},{"key":"23_CR6","doi-asserted-by":"crossref","first-page":"193","DOI":"10.2337\/dc08-9025","volume":"32","author":"DM Nathan","year":"2009","unstructured":"Nathan DM, Buse JB, Davidson MB, et al; American Diabetes Association; European Association for Study of Diabetes. Medical Management of Hyperglycemia in Type 2 Diabetes: A consensus algorithm for the initiation and adjustment of therapy. Diabetes Care. 2009;32:193\u2013203.","journal-title":"Diabetes Care"},{"key":"23_CR7","doi-asserted-by":"crossref","first-page":"540","DOI":"10.4158\/EP.15.6.540","volume":"15","author":"HW Rodbard","year":"2009","unstructured":"Rodbard HW, Jellinger PS, Davidson JA, et al. Statement by an American Association of Clinical Endocrinologists\/American College of Endocrinology consensus panel on type 2 diabetes mellitus: an algorithm for glycemic control. Endoc Pract. 2009;15:540\u2013559.","journal-title":"Endoc Pract"},{"key":"23_CR8","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.2337\/dc12-0413","volume":"25","author":"SE Inzucchi","year":"2012","unstructured":"Inzucchi SE, Bergenstal RM, Buse JB, et al; American Diabetes Association; European Association for Study of Diabetes. Management of hyperglycemia in type 2 diabetes: A patient centered approach. Position Statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2012;25:1364\u20131379.","journal-title":"Diabetes Care"},{"key":"23_CR9","unstructured":"CONSORT. CONSORT 2010 checklist of information to include when reporting a randomized trial. Available at: http:\/\/www.consort-statement.org\/consort-statement\/ . Accessed Jan 15 2013."},{"key":"23_CR10","doi-asserted-by":"crossref","first-page":"2594","DOI":"10.1001\/jama.2012.87802","volume":"308","author":"G Piaggio","year":"2012","unstructured":"Piaggio G, Elbourne DR, Pocock SJ, Evans SJ, Altman DG. Reporting of noninferiority and equivalence randomized trials extension of the CONSORT 2010 statement. JAMA. 2012;308:2594\u20132604.","journal-title":"JAMA"},{"key":"23_CR11","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1111\/j.1463-1326.2011.01530.x","volume":"14","author":"J Wainstein","year":"2012","unstructured":"Wainstein J, Katz L, Engel SS, et al. Initial therapy with the fixed-dose combination of sitagliptin and metformin results in greater improvement in glycaemic control compared with pioglitazone monotherapy in patients with type 2 diabetes. Diabetes Obes Metab. 2012;14:409\u2013418.","journal-title":"Diabetes Obes Metab"},{"key":"23_CR12","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1111\/j.1463-1326.2010.01334.x","volume":"13","author":"R Arechavaleta","year":"2011","unstructured":"Arechavaleta R, Seck T, Chen Y, et al. Efficacy and safety of treatment with sitagliptin or glimepiride in patients with type 2 diabetes inadequately controlled on metformin monotherapy: a randomized, double-blind, non-inferiority trial. Diabetes Obes Metab. 2011;13:160\u2013168.","journal-title":"Diabetes Obes Metab"},{"key":"23_CR13","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1111\/j.1742-1241.2011.02656.x","volume":"65","author":"R Pratley","year":"2011","unstructured":"Pratley R, Nauck M, Bailey T, et al; 1860-LIRADPP-4 Study Group. One year liraglutide treatment offers sustained and more effective glycaemic control and weight reduction compared with sitagliptin, both in combination with metformin, in patients with type 2 diabetes: a randomized, parallel-group, open-label trial. Int J Clin Pract. 2011;65:397\u2013407.","journal-title":"Int J Clin Pract"},{"key":"23_CR14","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1002\/dmrr.1114","volume":"26","author":"AJ Scheen","year":"2010","unstructured":"Scheen AJ, Charpentier G, Ostgren CJ, Hellqvist A, Gause-Nilsson I. Efficacy and safety of saxagliptin in combination with metformin compared with sitagliptin in combination with metformin in adult patients with type 2 diabetes mellitus. Diabetes Metab Res Rev. 2010;26:540\u2013549.","journal-title":"Diabetes Metab Res Rev"},{"key":"23_CR15","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/S0140-6736(10)60590-9","volume":"376","author":"RM Bergenstal","year":"2010","unstructured":"Bergenstal RM, Wysham C, MacConell L, et al; DURATION-2 Study Group. Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomized trial. Lancet. 2010;376:431\u2013439.","journal-title":"Lancet"},{"key":"23_CR16","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1111\/j.1463-1326.2007.00839.x","volume":"10","author":"R Scott","year":"2008","unstructured":"Scott R, Loeys T, Davies MJ, Engel SS. Efficacy and safety of sitagliptin when added to ongoing metformin therapy in patients with type 2 diabetes. Diabetes Obes Metab. 2008;10:959\u2013969.","journal-title":"Diabetes Obes Metab"},{"key":"23_CR17","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/S0140-6736(12)60691-6","volume":"380","author":"B Gallwitz","year":"2012","unstructured":"Gallwitz B, Rosenstock J, Rauch T, et al. 2-Year efficacy and safety of linagliptin compared with glimepiride in patients with type 2 diabetes inadequately controlled on metformin: a randomized, double-blind, non-inferiority trial. Lancet. 2012;380:475\u2013483.","journal-title":"Lancet"},{"key":"23_CR18","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1111\/j.1463-1326.2012.01590.x","volume":"14","author":"T Haak","year":"2012","unstructured":"Haak T, Meinicke T, Jones R, Weber S, Eynatten M, Woerle Hj. Initial combination of linagliptin and metformin improves glycaemic control in type 2 diabetes: a randomized, double-blind, placebo-controlled study. Diabetes Obes Metab. 2012;14:565\u2013574.","journal-title":"Diabetes Obes Metab"},{"key":"23_CR19","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1111\/j.1463-1326.2010.01326.x","volume":"13","author":"MR Taskinen","year":"2011","unstructured":"Taskinen MR, Rosenstock J, Tamminen I, et al. Safety and efficacy of linagliptin as add-on therapy to metformin in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled study. Diabetes Obes Metab. 2011;13:65\u201374.","journal-title":"Diabetes Obes Metab"},{"key":"23_CR20","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1111\/j.1464-5491.2010.02938.x","volume":"27","author":"C Filozof","year":"2010","unstructured":"Filozof C, Gautier JF. A comparison of efficacy and safety of vildagliptin and gliclazide in combination with metformin in patients with Type 2 diabetes inadequately controlled with metformin alone: a 52-week, randomized study. Diabet Med. 2010;27:318\u2013326.","journal-title":"Diabet Med"},{"key":"23_CR21","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1111\/j.1463-1326.2009.01080.x","volume":"11","author":"L Blonde","year":"2009","unstructured":"Blonde L, Dagogo-Jack S, Banerji MA, et al. Comparison of vildagliptin and thiazolidinedione as add-on therapy in patients inadequately controlled with metformin: results of the GALIANT trial \u2014 a primary care, type 2 diabetes study. Diabetes Obes Metab. 2009;11:978\u2013986.","journal-title":"Diabetes Obes Metab"},{"key":"23_CR22","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1111\/j.1463-1326.2008.00994.x","volume":"11","author":"E Ferrannini","year":"2009","unstructured":"Ferrannini E, Fonseca V, Zinman B, et al. Fifty-two-week efficacy and safety of vildagliptin vs. glimepiride in patients with type 2 diabetes mellitus inadequately controlled on metformin monotherapy. Diabetes Obes Metab. 2009;11:157\u2013166.","journal-title":"Diabetes Obes Metab"},{"key":"23_CR23","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.1111\/j.1742-1241.2010.02510.x","volume":"64","author":"B Goke","year":"2010","unstructured":"Goke B, Gallwitz B, Eriksson J, Hellqvist A, Nilsson-Gause I. Saxagliptin is non-inferior to glipizide in patients with type 2 diabetes mellitus inadequately controlled on metformin alone: a 52 week randomized controlled trial. Int J Clin Pract. 2010;64:1619\u20131631.","journal-title":"Int J Clin Pract"},{"key":"23_CR24","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.2337\/dc08-1984","volume":"32","author":"RA Defronzo","year":"2009","unstructured":"Defronzo RA, Hissa MN, Garber AJ, et al; Saxagliptin 014 Study Group. The efficacy and safety of saxagliptin when added to metformin therapy in patients with inadequately controlled type 2 diabetes with metformin alone. Diabetes Care. 2009;32:1649\u20131655.","journal-title":"Diabetes Care"},{"key":"23_CR25","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1111\/j.1742-1241.2008.01933.x","volume":"63","author":"MA Nauck","year":"2009","unstructured":"Nauck MA, Ellis GC, Fleck PR, Wilson CA, Mekki Q. Efficacy and safety of adding the dipeptidyl peptidase-4 inhibitor alogliptin to metformin therapy in patients with type 2 diabetes inadequately controlled with metformin monotherapy; a multicentre, randomized, double-blind, placebo-controlled study. Int J Clin Pract. 2009;63:46\u201355.","journal-title":"Int J Clin Pract"},{"key":"23_CR26","unstructured":"Takeda Pharmaceuticals. Takeda resubmits new drug applications to the United States Food and Drug Administration for alogliptin and the fixeddose combination alogliptin and pioglitazone. Available at: http:\/\/www.takeda.us\/newsroom\/press_release_detail.aspx?year=2012&id=244 . Accessed Jan 22 2013."},{"key":"23_CR27","unstructured":"US Food and Drug Administration. FDA approves three new drug treatments for type 2 diabetes. Available at: http:\/\/www.fda.gov\/NewsEvents\/Newsroom\/PressAnnouncements\/ucm336942.htm . Accessed Jan 28 2013."},{"key":"23_CR28","unstructured":"Merck. Putting patients first by addressing significant unmet medical needs: update on cardiovascular outcomes study with Januvia. Available at: http:\/\/www.merck.com\/mrl\/clinical_trials\/outcomes_study.html . Accessed March 21 2013."},{"key":"23_CR29","unstructured":"ClinicalTrials.gov. Sitagliptin cardiovascular outcome study (0431-082 AM1) (TECOS). Available at: http:\/\/clinicaltrials.gov\/ct2\/show\/NCT00790205?term=DPP+4+inhibitors&rank=132 . Accessed March 21 2013."},{"key":"23_CR30","unstructured":"ClinicalTrials.gov. Does Saxagliptin Reduce the Risk of Cardiovascular Events When Used Alone or Added to Other Diabetes Medications (SAVOR-TIMI 53). Available at: http:\/\/clinicaltrials.gov\/ct2\/show\/NCT01107886?term=saxagliptin&cond=%22Coronary+Artery+Disease%22&rank=2 . Accessed March 21 2013."}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-013-0023-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12325-013-0023-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-013-0023-6","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,2]],"date-time":"2019-06-02T07:56:03Z","timestamp":1559462163000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12325-013-0023-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,4]]},"references-count":30,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2013,4]]}},"alternative-id":["23"],"URL":"https:\/\/doi.org\/10.1007\/s12325-013-0023-6","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,4]]}}}